Treatment
Semaglutide clinical trials
We’re tracking 138 recruiting studies that include Semaglutide, each written for real people, not researchers, below.
Recruiting studies
- NCT06894784RecruitingPhase 3
Combining two diabetes drugs with an automated insulin pump
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
Montreal, QuebecAges 18 years+ - NCT07325500RecruitingPhase 2
Low dose GLP-1 for heart health in HIV
This study tests a very low dose of a medication called a GLP-1 receptor agonist to see if it can improve heart and metabolic health in people with HIV who have excess weight.
Houston, TexasAges 18 years+ - NCT07294950RecruitingPhase 3
What happens when you stop semaglutide after weight loss
This study looks at what happens to your body and weight when you stop taking semaglutide (Wegovy/Ozempic) after losing at least 10% of your starting weight. The goal is to understand how your metabolism and heart health change once the medication is paused.
Toronto, OntarioAges 18–75 - NCT07225816RecruitingPhase 1
How fasting affects stomach food with GLP-1 drugs
This study looks at how long fasting and temporarily stopping certain diabetes or weight-loss medications (like semaglutide or liraglutide) affects how much food stays in your stomach. It may help understand how these medications work in people who are overweight.
Cypress, CaliforniaAges 18 years+ - NCT07728383RecruitingPhase 4
Obesity treatment study using tongue-applied semaglutide
This trial tests a new way to deliver semaglutide through a strip placed on the tongue for weight loss in adults with obesity. It may help you lose weight without a needle.
Minneapolis, MinnesotaAges 18–65 - NCT07668414RecruitingPhase 3
Study comparing Zenagamtide and Semaglutide for weight loss
This trial tests a new medicine Zenagamtide to see if it helps people with excess weight lose more weight than Semaglutide, an existing weight loss drug. You may join if you are an adult with overweight or obesity but do not have diabetes.
Lancaster, CaliforniaAges 18 years+ - NCT07527195RecruitingPhase 1
Study of CagriSema on Muscle Health in Adults with Obesity
This study tests a new medication called CagriSema to understand how it affects muscle health while helping people lose weight. You'll be in the trial for about a year, and researchers will monitor your muscle function and body composition.
Aarhus NAges 50–70 - NCT07465965RecruitingPhase 1
Weight loss study of semaglutide nasal spray in overweight or obese adults
This study tests a nasal spray containing semaglutide (a GLP-1 receptor agonist) to see if it helps adults who are overweight or obese lose weight. It may be an option if you have a BMI between 27 and 35 and have not used other weight loss medications recently.
Secaucus, New JerseyAges 18–65 - NCT07272343RecruitingPhase 4
Semaglutide vs. diet changes for new type 2 diabetes
This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.
Jiangxi, NanchangAges 18–75 - NCT06934655RecruitingPhase 3
Starting semaglutide again after weight-loss surgery in teens
This trial tests if restarting semaglutide (a weekly injection for weight loss) soon after sleeve gastrectomy helps teens with severe obesity keep losing weight. It is for patients who were already taking semaglutide before their surgery.
Los Angeles, CaliforniaAges 12–18 - NCT05569772RecruitingPhase 3
Semaglutide for prediabetes after gestational diabetes
This trial studies whether semaglutide can help women with prediabetes after past gestational diabetes return to better blood sugar levels and lower progression to diabetes. It is designed for women who are no longer breastfeeding and can use effective birth control.
AalstAges 18 years+ - NCT05630586RecruitingPhase 2
Semaglutide shot for early stroke recovery
This Phase 2 study tests whether a semaglutide injection given under the skin soon after an acute ischemic stroke can improve recovery. It may help reduce disability, especially if treatment starts within about 4.5 hours of symptom onset.
AarhusAges 18 years+ - NCT05780905RecruitingPhase 4
Semaglutide study for brain blood flow in type 2 diabetes
This trial tests whether semaglutide changes blood flow in the brain and the brain’s “barrier” (how well the brain is protected) in people with type 2 diabetes. It may help researchers understand brain-related effects of diabetes treatment using scans and blood tests.
Seattle, WashingtonAges 40–65 - NCT07770841RecruitingPhase 3
Oral medication for weight loss study
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
Birmingham, AlabamaAges 18 years+ - NCT07732426Recruiting
Semaglutide and brain response to food in obesity with food addiction
This trial tests if semaglutide can change how your brain responds to food cues, like seeing or smelling food, in people with obesity and a tendency toward food addiction. It may help understand why some people struggle with overeating and how this medication could help.
SeoulAges 19–50 - NCT07673900RecruitingPhase 1
Testing a new patch for semaglutide in healthy overweight adults
This trial tests a new skin patch (VX-201) that delivers semaglutide, a medicine used for weight management, compared to a standard injection. It is for healthy overweight or obese adults who are not taking other weight loss medications.
Tempe, ArizonaAges 18–60 - NCT07668388RecruitingPhase 2
Testing different doses of UBT251 for type 2 diabetes
This trial tests a new medicine, UBT251, to see how well it lowers blood sugar in people with type 2 diabetes. It compares different doses to find the best one for you.
Birmingham, AlabamaAges 18–75 - NCT07662213RecruitingPhase 3
Elecoglipron vs semaglutide for type 2 diabetes
This study tests an experimental diabetes pill (elecoglipron) to see if it works as well as a current medicine, semaglutide, for people with type 2 diabetes who also have heart risk factors. It aims to help better control blood sugar and weight.
Birmingham, AlabamaAges 18 years+ - NCT07651319RecruitingPhase 1/Phase 2
IL-2 and Semaglutide Treatment for Alzheimer's Disease
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
Houston, TexasAges 50–86 - NCT07621419Recruiting
Semaglutide for Type 2 Diabetes in Real-World Care
This study tests how well a diabetes medication called semaglutide works when prescribed in everyday clinical practice in Argentina. Semaglutide comes in two forms—a pill or an injection—and the study tracks how much it lowers blood sugar over one year.
Buenos Aires, Buenos AiresAges 18 years+ - NCT07581145RecruitingPhase 3
Semaglutide for Faster Healing of Diabetic Foot Ulcers
This study tests whether a diabetes medication called semaglutide can help foot ulcers heal faster in people with type 2 diabetes. If it works, it could offer a new treatment option for a common and serious diabetes complication.
CopenhagenAges 18–90 - NCT07564414RecruitingPhase 3
Weight Loss Study Comparing Two Doses of CagriSema
This study tests whether a new combination medication called CagriSema (in two different doses) helps people with obesity lose weight. You may qualify if you're 18 or older, have a BMI of 35 or higher, and either don't have type 2 diabetes or have it well-controlled.
Birmingham, AlabamaAges 18 years+ - NCT06387199RecruitingPhase 2/Phase 3
Weekly semaglutide with closed-loop system for type 1 diabetes
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
Montreal, QuebecAges Any age - NCT07523633RecruitingPhase 2
Semaglutide to help reduce cannabis use disorder
This trial tests whether a medication called semaglutide (used for weight management) can help adults with cannabis use disorder cut down or stop using cannabis. Researchers want to see if it reduces cravings and use while also monitoring overall health.
FrederiksbergAges 18–70
What Semaglutide is being studied for
Conditions with recruiting Semaglutide studies.
Common questions
- Are there clinical trials studying Semaglutide?
- Yes. Clin2 currently lists 138 recruiting studies that include Semaglutide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Semaglutide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Semaglutide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Semaglutide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.